SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* RMI Investments S.a.r.l. (Last) (First) (Middle) 7, ROBERT STUMPER (Street) GRAND DUCHY N4 L-2557 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/01/2016	3. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [ CLSD ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	335,769(1)	D(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	(3)	(3)	Common Stock	1,179,398(4)	(3)	D(2)

1. Name and Address of Reporting Person* RMI Investments S.a.r.l. (Last) (First) (Middle) 7, ROBERT STUMPER (Street) GRAND DUCHY N4 L-2557 (City) (State) (Zip)

1. Name and Address of Reporting Person* RusnanoMedInvest LLC (Last) (First) (Middle) 44, BLDG. 1, KRASNOBOGATYRSKAYA STREET (Street) MOSCOW 1Z 107076 (City) (State) (Zip)

Explanation of Responses:

1. The number of shares of common stock reflects a 1-for-2.2 reverse stock split of the Issuer's common stock effected on May 11, 2016.

2. The Reporting Person is a wholly-owned subsidiary of Rusnano MedInvest LLC ("RMI LLC"). RMI LLC is the beneficiary of the Reporting Person.

3. Each share of the Series B Preferred Stock is convertible, at any time, at the holder's election, into 0.454545 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert into 0.454545 shares of the Issuer's common stock. The Series B Preferred Stock has no expiration date.

4. The number of underlying shares of common stock reflects a 1-for-2.2 reverse stock split of the Issuer's common stock effected on May 11, 2016.

Remarks:

	/s/ Vladimir Gurdus, CEO of RMI Partners, LLC, Managing Company for Rusnano MedInvest, LLC, its Category A Manager	06/01/2016
	/s/ Vladimir Gurdus, CEO of RMI Partners, LLC its Managing Company	06/01/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.